REGENXBIO maintains its clinical roadmap, targeting a 2027 BLA filing for its Duchenne muscular dystrophy candidate and preparing for key wet AMD data readouts in Q4 2026.
The release confirms RGX-202 BLA submission is on track for Q1 2027 and wet AMD topline data from ATMOSPHERE and ASCENT are expected in Q4 2026. Those milestones keep the pipeline timeline intact, but the excerpt contains no revenue, cash or earnings figures, so the near-term stock reaction depends on details not shown.
The article lists topline data from the pivotal wet AMD studies ATMOSPHERE and ASCENT expected in Q4 2026, an RGX-202 BLA submission targeted for Q1 2027, and potential accelerated approval in 2H 2027.
The excerpt refers to third-quarter 2026 financial results but provides no revenue, cash or earnings numbers.
REGENXBIO confirmed its clinical development timeline, maintaining a Q1 2027 target for the RGX-202 BLA submission in Duchenne muscular dystrophy. The company also expects pivotal topline data from its wet AMD studies, ATMOSPHERE and ASCENT, by the end of 2026.
The company is focused on a Q1 2027 BLA submission for RGX-202 and expects pivotal data from its wet AMD studies in Q4 2026.
While the company reported third-quarter 2026 results, the provided text did not include specific revenue, cash, or earnings figures.